ABSTRACT
(4.4 % (2,637/59,431) of the total cohort, but 38 % (2,637/ 6,942) of patients with SLN mapping and positive nodes) met inclusion criteria for ACOSOG Z0011, had 1 or 2 positive lymph nodes, and could have been spared an ALND. Of these 2,637 patients, 46 % received a completion ALND and 54 % received only SLN biopsy. Conclusions. Widespread implementation of ACOSOG Z0011 trial results could potentially spare 38 % of older breast cancer patients who undergo SLN mapping with positive lymph nodes an ALND. However, 54 % of these patients are already managed with SLN biopsy alone, lessening the impact of this trial on clinical practice in older breast cancer patients.
Sentinel lymph node (SLN) biopsy is currently the standard of care for staging the clinically negative axilla in breast cancer patients, with axillary lymph node dissection (ALND) reserved for patients with clinical axillary metastases or metastases found on SLN biopsy. [1] [2] [3] However, this treatment paradigm has changed based on the results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 randomized trial initially reported in 2010. 4, 5 This trial included patients with clinically node-negative invasive breast cancer treated with lumpectomy and whole breast radiation. Patients with one or two positive SLNs were randomized to undergo completion ALND or observation. In this select group of patients, no significant difference in survival or locoregional recurrence was observed between the patients undergoing SLN biopsy alone and those who received a completion ALND. 4, 5 The ACOSOG Z0011 study has been heralded by many as a ''practice changing trial,'' altering the treatment paradigm for axillary metastases and sparing eligible women the morbidity of a completion ALND without sacrificing survival or local control. [6] [7] [8] However, others have argued that the stringent inclusion criteria associated with the trial limits the true clinical significance of these findings, as a relatively small proportion of patients will be eligible. 9 Given this, we sought to evaluate the potential impact of the ACOSOG Z0011 trial on the axillary surgical management of older breast cancer patients by determining the proportion of Medicare breast cancer patients eligible for ACOSOG Z0011. To further evaluate the potential impact, a secondary objective was to examine current practice patterns with regards to axillary surgical management in this older population.
METHODS
This study was approved by the University of Wisconsin Institutional Review Board and granted a waiver of consent.
Data Source
The linked Surveillance, Epidemiology and End Results (SEER)-Medicare database was used to identify patients diagnosed with breast cancer from 2001 to 2007. The SEER cancer registries include information on patient demographics, tumor characteristics, first course of treatment, and survival for persons newly diagnosed with cancer. For individuals who are eligible for Medicare services, the SEER-Medicare database includes claims for covered health care services, including hospital, physician, outpatient, home health, and hospice bills. The SEERMedicare dataset has successfully linked 93 % of individuals over age 65 at diagnosis to their Medicare record. 10, 11 In 2000, SEER regions included approximately 26 % of the U.S. population. 11 The SEER-Medicare data is an established resource for studying cancer practice patterns in older patients. 12 
Patient Selection

Patient-Related Variables
Basic demographics were obtained from SEER data. The Deyo implementation of the Charlson comorbidity index was used to assess patient comorbidities. 13, 14 The 6th edition American Joint Committee on Cancer (AJCC) staging was used to assign stage based on SEER tumor size and number of positive nodes. 15 Estrogen and progesterone receptor (ER/PR) status and tumor grade also were assessed using SEER.
Treatment-Related Variables
Receipt of chemotherapy, radiation, and surgical therapy were defined using ICD-9 and CPT codes ( Table 1) . The most definitive surgery (i.e., mastectomy if it followed lumpectomy) was used to assign surgical management of the breast. We determined definitive axillary surgery based on an algorithm using CPT codes and number of lymph nodes examined (Table 1) . Figure 1 demonstrates how the ACOSOG Z0011 eligibility criteria were applied. To identify the proportion of patients for whom the ACOSOG Z0011 trial data can be applied, we considered only patients who underwent a SLN mapping procedure (patients with no surgical axillary staging procedure were excluded). We were unable to directly assess clinical axillary lymph node status using the SEER-Medicare database. Therefore, we used receipt of a SLN biopsy as a surrogate for clinically negative axilla; patients who did not have SLN mapping performed but had Health CPT: 19140, 19180, 19182, 19300, 19303, 19304, 19200, 19220, 19240, 19305-19307 an ALND performed were assumed to have clinically evident disease at the time of presentation and therefore not eligible for ACOSOG Z0011. We excluded patients with large tumors ([5 cm or T3/T4) or who received neoadjuvant chemotherapy. Patients who underwent lumpectomy followed by whole-breast radiation as their definitive local management were considered eligible. Finally, we examined the number of positive nodes. We are unable to distinguish within the SEER-Medicare database the number of nodes positive at the time of SLN versus the total number of nodes positive after the completion ALND. We instead categorized the number of positive nodes as 1-2, 3, or C4 positive lymph nodes to allow full consideration of which patients are most likely eligible for ACOSOG Z0011 (those with 1 or 2 positive lymph nodes), possibly eligible (3 positive lymph nodes), and unlikely to be eligible (C4 positive lymph nodes).
Determination of ACOSOG Z0011 Eligibility
Analysis
The ACOSOG Z0011 inclusion criteria was applied to the overall cohort to determine the proportion of patients within the SEER Medicare database with newly diagnosed invasive breast cancer who would meet the eligibility criteria. 4, 5 Briefly, patients in ACOSOG Z0011 were considered eligible for the trial if they had histologically confirmed breast cancer \5 cm in size, were clinically node negative, underwent lumpectomy with planned whole breast radiation, and had 1-2 SLNs with metastases identified (without matting or gross extranodal extension). Descriptive statistics for demographic and clinical characteristics were generated. Actual surgical axillary management of the cohort eligible for ACOSOG Z0011 was then assessed. The characteristics of patients meeting the ACOSOG Z0011 inclusion criteria who underwent completion ALND were compared with those who forwent further axillary surgery with v 2 tests using Stata (College Station, TX). Similar data and statistics for those undergoing mastectomy that would have otherwise been eligible under ACOSOG Z0011 (if they had undergone lumpectomy) also were assessed. (Table 2 ). An additional 258 patients had 3 positive lymph nodes.
RESULTS
Of
Of the 2,637 patients eligible for ACOSOG Z0011, 1,214 (46 %) received a completion ALND and 1,423 (54 %) did not receive additional axillary surgery beyond the SLN biopsy. Table 3 presents the demographics of these two groups. Patients who received ALND were more likely to be younger (p \ 0.001), have fewer comorbidities (p = 0.05), and be more likely to receive chemotherapy (p \ 0.001).
Given the high rate of SLN only in the lymph nodepositive lumpectomy patients, practice patterns for those patients who underwent mastectomy as the definitive breast surgery were examined to see how rates of completion ALND compared. Of the cohort of 6,241 patients with a primary tumor \5 cm who underwent SLN mapping, 2,688 underwent mastectomy. One or two positive nodes were identified in 70 % (n = 1,881), of whom 18 % received postmastectomy radiation. Of the 1,881 patients, 877 (53 %) received a completion ALND in actual practice and were more likely be younger (p \ 0.001) and to receive chemotherapy (p \ 0.001). In general, axillary surgery practices for patients undergoing mastectomy paralleled that seen for patients treated with lumpectomy and whole breast radiation.
DISCUSSION
In this observational study of Medicare recipients, we estimated that 38 % of older breast cancer patients with who underwent SLN mapping with positive lymph nodes could be spared an ALND based on ACOSOG Z0011 criteria. This is in line with other single-institution experiences who have reported rates of approximately 45 %. 7, 9 From the perspectives of these women spared an ALND and its concomitant morbidity (i.e., lymphedema, paresthesias), ACOSOG Z0011 is clearly a practicechanging trial. [16] [17] [18] However, in our population-based dataset, we also observed that 54 % of ACOSOG Z0011 eligible patients were already forgoing a completion ALND in exchange for observation alone prior to 2007. Before the results of ACOSOG Z0011 reported in 2010, several observational studies reported similar survival and local recurrence outcomes for patients with early-stage primary tumors and a low burden of axillary disease, regardless of whether they underwent a completion ALND or not. [19] [20] [21] [22] [23] [24] [25] [26] [27] Additional indirect evidence supporting avoidance of ALND came from two randomized, controlled trials that compared ALND versus no ALND in patients with a clinically negative axilla (SLN was not performed in either study). 28, 29 In both trials, survival and local recurrence were the same. Although these studies cannot be directly extrapolated to patients with proven nodal metastases, they further support the trend away from ALND in breast cancer and may have contributed to the patterns of care observed in our study.
What about those patients with SLN metastases who underwent mastectomy? In all reported series as well as our own study, the primary reason why patients would not meet eligibility criteria for ACOSOG Z0011 was receipt of a mastectomy as the definitive breast surgery; one study reported that almost 75 % of patients with positive SLNs would be spared an ALND if they elected or were candidates for breast-conserving therapy. 7, 9 Although patients who received mastectomy were excluded from ACOSOG Z0011, we observed that many Medicare patients with positive lymph nodes treated with mastectomy were forgoing further axillary surgery if only 1-2 axillary lymph nodes are found to be positive (877 patients or 47 %).
There are some limited data to support this practice. The recently published International Breast Cancer Study Group Trial 23-01 randomized patients with SLN micrometastases (\2 mm) to completion ALND versus observation. 30 Nine percent of patients enrolled in the trial were treated with mastectomy, with no difference in breast Impact of ACOSOG Z0011 on Practicecancer events in this very low-risk subgroup, regardless of axillary surgery performed. 30 A similar trend can be observed in the NSABP-B32 trial, which validated the SLN concept by randomizing patients with clinically negative axilla to SLN followed by ALND versus SLN followed by ALND only if the SLN was positive. In this trial, all patients with a positive SLN underwent completion dissection. However, SLNs of patients found to be node-negative underwent central review using both routine and immunohistochemical staining; occult metastases were identified in 15.9 % of node-negative patients. Of these patients, 107 were managed with mastectomy. 1 As observed in the IBCSG trial, no detriment in outcome was observed for these mastectomy patients with very low burden axillary disease treated with observation alone. 30 Although far from definitive, data such as this provide some supporting evidence that the trend away from ALND observed in our SEER-Medicare cohort may not be resulting in poorer outcomes for these women.
There are several limitations to this study. First, our analysis of the SEER Medicare database describes the projected impact of the ACOSOG Z0011 study on the Medicare population rather than change in actual practice due to the dissemination of ACOSOG Z0011 findings. However, population level data assessing actual dissemination will not be available for several years. Second, the SEER Medicare database does not provide information on the number of positive SLNs identified; we only know the total number of positive lymph nodes examined. Therefore, we cannot identify our eligible cohort precisely. We addressed this limitation by presenting categories of the number of positive nodes. Of the 3,312 patients who underwent SLN mapping with positive lymph nodes treated with lumpectomy and radiation, we estimated that 80 % had 1-2, 8 % had 3, and 12 % had 4 or more positive lymph nodes. In our analysis, we considered those with 1-2 nodes positive to be our most conservative estimate of potential eligible patients, although this likely underestimates eligible patients as some of those patients with 3 positive nodes could be considered eligible (if some of those nodes were identified at ALND rather than SLN). Additionally, we used receipt of SLN mapping as a surrogate for clinically negative axilla. This may underestimate eligible patients if some surgeons had slow adoption of SLN biopsy as an alternative to ALND as standard of care. 31 A final limitation of our study is that our analysis is limited to the Medicare population, and we cannot make conclusions regarding the potential impact of ACOSOG Z0011 on younger populations. However, given that patients [65 years of age comprise more than 40 % of all new breast cancer diagnoses and may be the patients most likely to have ACOSOG Z0011 data applied to them, our findings have significant clinical relevance.
CONCLUSIONS
We determined that *38 % of older breast cancer patients who underwent SLN mapping and were found to have positive lymph nodes would be spared an ALND in the era of ACO-SOG Z0011. However, in our pre-ACOSOG Z0011 dataset, we observed that \50 % of eligible older breast cancer patients were receiving a completion ALND even before trial results were reported, thereby dampening the true impact of this trial on clinical practice. It is noteworthy that the trend away from completion ALND in older patients with lowvolume axillary disease extended in our cohort to patients receiving mastectomy. Future work will need to better define the role of completion ALND for subgroups who do not meet eligibility for AOCOSOG Z0011, but for whom the risk of axillary recurrence is low, particularly those patients with low-volume axillary disease treated with mastectomy.
